메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Alphamab Oncology Reports 2025 Interim Results and Business Highlights

SUZHOU, China, Aug. 29, 2025 -- Alphamab Oncology (stock code: 9966.HK) reported interim financial results for the six months ended June 30, 2025 and highlighted recent business progress. Financial Summary For the six months ended June 30, 2025, we recorded total revenue of RMB 319.44 million, an increase of 84.05% compared with the first half of 2024. Meanwhile, product revenue (attributed to the Company) amounted to RMB 67.02 million. For the six months ended June 30, 2025, our R&D expenditure amounted to RMB 253.16 million, an increase of 30.14% compared with the fir
- 김갑성 기자
- 2025-08-29 09:53
Mayapada Healthcare Holds Commencement Ceremony for an International Hospital in the Batam Tourism and International Healthcare SEZ

JAKARTA, Indonesia, Aug. 29, 2025 -- Mayapada Healthcare (IDX:SRAJ), the healthcare services arm of Mayapada Group, held a commencement ceremony to mark the development of its international-standard hospital, Mayapada Apollo Batam International Hospital (MABIH), located in Batam Tourism and International Healthcare Special Economic Zone (SEZ), Sekupang, Batam, Riau Islands. The ceremony was led by the Chairman of Batam Indonesia Free Trade Zone Authority (BP Batam), Amsakar Achmad. The ceremony marks a significant step in strengthening Indonesia's national healthcare ecosystem while reducing
- 김갑성 기자
- 2025-08-29 09:23
HEC Group and JungKwanJang Form Strategic Alliance to Drive a New Era in Eastern Tonic Health

SINGAPORE, Aug. 29, 2025 -- The JungKwanJang delegation included Kim Yang-jin, Director General of the Overseas Business Division; Jung Jong, Director General of the Asia-Pacific Business Division; and Kim Jong-sik, Director of the Future Business Research Institute, along with five other representatives. HEC Group was represented by Director and General Manager Tang Xinfa; Lu Yuxin, Director and General Coordinator of the Health Industry; Li Wenjia, Deputy General Coordinator of the Health Industry and Dean of the Health Research Institute; Chen Hao, General Manager of HEC Pharmacy C
- 김갑성 기자
- 2025-08-29 08:15
Everest Medicines Announces Interim Results for First Half of 2025

SHANGHAI, Aug. 29, 2025 -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced its interim results for the first half of 2025 along with a corporate update. "In the first half of 2025, Everest Medicines accelerated its transformation into a leading global biopharmaceutical company by deepening our 'dual-engine' strategy," commented Rogers Yongqing Luo, CEO of Everest Medicines. "We have built a co
- 김갑성 기자
- 2025-08-29 07:52
Celaid Therapeutics have executed a collaborative research agreement with AGC on Expansion and Functional Evaluation of iPSC-HSPCs

TOKYO, Aug. 28, 2025 -- Celaid Therapeutics Inc. ("Celaid") have executed a collaborative research agreement with AGC Inc. ("AGC") to advance iPS cell-derived hematopoietic stem and progenitor cells (iPSC-HSPCs). The collaboration aims to combine Celaid's proprietary platform of hematopoietic stem cell (HSC) expansion technology with AGC's iPSC technology to accelerate robust and scalable expansion of iPSC-HSPCs. In this project, Celaid's human HSC expansion technology will be applied to AGC's iPSC-HSPCs. The functionality of the expanded cells will be evaluated thr
- 김갑성 기자
- 2025-08-28 22:00
Coventry Responds to Lapetus's Secrecy Claim

[ 메디채널 황정호 기자 ] Urges transparency on life expectancy accuracy Following Lapetus's imminent closure, argues elimination of any claim to trade secret protection TALLAHASSEE, Fla., Aug. 28, 2025 -- Coventry First LLC ("Coventry"), the market leader in life settlements, this week filed a legal response opposing Lapetus Solutions, Inc.'s ("Lapetus") attempt to block disclosure of statutorily required life expectancy audit reports. The filing underscores Coventry's long-held view that the integrity of the life settlement market demands transparency around the ac
- 황정호 기자
- 2025-08-28 21:05
D3 Bio, Inc. Announces FDA Breakthrough Therapy Designation and Orphan Drug Designation for D3S-001 for the Treatment of Patients with KRAS G12C-Mutated Cancers

Breakthrough Therapy Designation was granted for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have had prior treatment with platinum-based chemotherapy and anti-PD-(L)1 antibody but have not been previously treated with a KRAS G12C inhibitor Orphan Drug Designation was granted for treatment of colorectal cancer (CRC) harboring KRAS G12C mutant protein. SHANGHAI, Aug. 28, 2025 -- D3 Bio, Inc, a clinical-stage oncology company focuses on discovery and development of precision oncology therapies
- 김갑성 기자
- 2025-08-28 21:00
LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company and Formation of Special Committee

BEIJING, Aug. 28, 2025 -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that its board of directors (the "Board") has received a revised preliminary non-binding proposal letter (the "Revised Proposal Letter"), dated August 26, 2025, from a consortium (the "Consortium") comprised of Oceanpine Investme
- 김갑성 기자
- 2025-08-28 20:00
뉴소프트 메디컬 시스템즈의 광자 계수 CT, 중국 최초 NMPA 승인

[ 메디채널 김갑성 기자 ] 선양, 중국 2025년 8월 28일 -- 의료 영상 솔루션 및 서비스 분야의 글로벌 선도기업 뉴소프트 메디컬 시스템즈(Neusoft Medical Systems)가 27일 자사의 NeuViz P10 광자 계수 CT(photon-counting CT)가 중국 국가약품감독관리국(National Medical Products Administration•NMPA)으로부터 시판 허가를 받았다고 밝혔다. 중국에서 광자 계수 CT가 승인된 건 NeuViz P10가 처음이다. NeuViz P10는 전 세계 최초로 8cm 검출기를 탑재한 와이드 바디 시스템이다. 광자 계수 CT는 차세대 영상 기술의 혁신으로 간주된다. X선을 먼저 빛으로 변환한 후 디지털 영상을 생성하는 기존 CT 스캐너와 달리 NeuViz P10은 카드뮴•아연•텔루라이드(CZT) 검출기를 사용해 각 X선 광자를 직접 포착해 디지털 신호로 변환한다. 이러한 직접적인 접근 방식은 훨씬 더 선명한 영상을 제공하고 환자의 방사선 노출을 줄이면서 서로 다른 종류의 조직을 구별하는 능력을 향상시킨다. 이러한 발전 덕분에 환자 심장의 미세 혈관을
- 김갑성 기자
- 2025-08-28 19:41
WuXi Biologics' Near-Term and Net-Zero Targets Approved by SBTi

[ 메디채널 김갑성 기자 ] Committed to net-zero across the value chain by 2050 Aligned with 1.5°C mitigation pathways, the most ambitious SBTi designation Leader in Green CRDMO to drive innovation for a healthier future SHANGHAI, Aug. 28, 2025 -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced its near-term and net-zero greenhouse gas (GHG) emissions reduction targets have been approved by the Science Based Targets initiative (SBTi). WuXi Biologics is one of the first companies in the industry t
- 김갑성 기자
- 2025-08-28 17:00

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-09-04_THU

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 09월 04일 12시 20분